Inhibitors of NF-κB activity used to treat diseases and conditions.

Abstract

The present invention relates to inhibitors of NFkappaB activity for the treatment of diseases and disorders, and discloses peptides and methods of use thereof for the treatment of various diseases and disorders, including inflammation, pain, oral mucositis, oral lesions, and cancer. The peptides modulate the activity of the transcription factor NFkappaB.

Description

[0001] This application is a divisional application of the international application filed on September 25, 2015, with application number PCT / US2015 / 052467 and the invention title "Inhibitor of NF κB activity for the treatment of diseases and symptoms". The international application entered the Chinese national phase on May 25, 2017, with application number 201580064157.3.

[0002] Cross-references to related applications

[0003] This application claims priority to U.S. Provisional Patent Application No. 62 / 055,982, filed September 26, 2014. The entire contents of that application are incorporated herein by reference.

[0004] Invention Field

[0005] Compositions and methods for treating and preventing diseases and symptoms caused by NF κB (nuclear factor-activated B cell κ light chain enhancer; NF kappa-B) dysregulation are disclosed. Technical Field

[0007] This invention relates to the use of the disclosed compounds for inhibiting NF-κB activation, for the prevention and treatment of various diseases caused by factors that interfere with the normal regulation of NF-κB, such as stress, injury, infection, inflammation, cytokines, free radicals, ultraviolet radiation, ionizing radiation, oxidized low-density lipoprotein, bacterial and viral products and antigens, immune disorders, and certain drugs and chemotherapy. Background of the Invention

[0009] NF-κB is a pathogenic factor in a wide range of diseases and conditions. It is involved in multiple pathways mediating cell proliferation, survival, apoptosis, adhesion, invasion, and angiogenesis in different cell types. A detailed list of diseases and conditions involving NF-κB dysregulation is provided below. Inhibiting NF-κB activation is a highly desirable target. Current clinical practice uses TNFα antagonists to treat diseases involving NF-κB. Invention Overview

[0011] This document discloses compositions and methods for inhibiting the activity or activation of NF-κB. The compounds disclosed herein are peptides, peptide mimics, or peptide-like compounds of 4-20 residues. In this application, the term peptide refers to the sum of peptides (i.e., standard peptides excluding peptide-like compounds and peptide mimics), peptide mimics, and peptide-like compounds. This invention relates to the peptides and related compounds of the invention for inhibiting NF-κB activation, differentially regulating genes affected by NF-κB, and methods for treating diseases and conditions in human or non-human patients requiring said treatment using said peptides and related compounds. Further features and advantages of the invention will be apparent from the following detailed description of the invention taken in conjunction with the accompanying drawings, which also illustrate the features of the invention by way of example.

[0012] In any embodiment of the invention, any peptide group, or any peptide group indicating its potential use in treating a disease or condition, may further be conditionally specified as containing at least one non-natural amino acid. In any embodiment of the invention, any peptide group, or any peptide group indicating its potential use in treating a disease or condition, may further be conditionally specified as containing at least one non-protein amino acid. In any embodiment of the invention, any peptide group, or any peptide group indicating its potential use in treating a disease or condition, may further be conditionally specified as containing at least one D-amino acid.

[0013] In any embodiment of the invention, the disclosed “peptide” includes “standard peptide” (a polymer of α-amino acids and / or imino acids without peptide bond modification, i.e., peptide excluding peptide analogs and peptide mimics) and embodiments relating to “standard peptide”.

[0014] In one embodiment, the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0015] Xxx-Ala-Pro-Glu

[0016] Wherein Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, Phe, 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (1). In another embodiment, the peptide of this motif does not include peptides containing the sequence LIAPEA (SEQ ID NO:061) and does not include peptides containing the sequence LWAEAK (SEQ ID NO:008), peptides containing the sequence LIAEAK (SEQ ID NO:009), peptides containing the sequence LVAEAK (SEQ ID NO:030), peptides containing the sequence LIANAK (SEQ ID NO:012), and peptides containing EQID NOS:041-113. NF κB inhibitory peptides containing a core sequence (1) and having a length of four to twenty amino acid residues are designated as peptides containing the core sequence (1).

[0017] In one embodiment of the peptide of the core sequence (1), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0018] Xxx-Ala-Pro-Glu

[0019] Wherein Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, or Phe. The peptide motif is designated as the core sequence (1-N). NF κB repressor peptides containing the core sequence (1-N) and having a length of four to twenty amino acid residues are designated as peptides containing the core sequence (1-N). In another embodiment, the peptide motif does not include peptides containing the sequence LIAPEA (SEQ ID NO:061) and does not include peptides containing the sequence LWAEAK (SEQ ID NO:008), LIAEAK (SEQ ID NO:009), LVAEAK (SEQ ID NO:030), LIANAK (SEQ ID NO:012), or EQ ID NOS:041-113.

[0020] In one embodiment of the peptide of the core sequence (1), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0021] Xxx-Ala-Pro-Glu

[0022] Where Xxx is selected from 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (1-U). NF κB repressive peptides containing the core sequence (1-U) and having a length of four to twenty amino acid residues are designated as peptides with the core sequence (1-U). In another embodiment, the peptide of the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include a peptide containing the sequence LWAEAK (SEQ ID NO:008), a peptide containing the sequence LIAEAK (SEQ ID NO:009), a peptide containing the sequence LVAEAK (SEQ ID NO:030), a peptide containing the sequence LIANAK (SEQ ID NO:012), or a peptide containing EQ ID NOS:041-113.

[0023] In one embodiment of the peptide of the core sequence (1), the NF κB repressor peptide is selected from peptides of a maximum length of twenty amino acid residues, comprising the following sequence:

[0024] YMAPEV (SEQ ID NO:001), IIAPEG (SEQ ID NO:002), TWAPES (SEQ ID NO:016), AWAPEA (SEQ ID NO:024), PSAPEN (SEQ ID NO:026), HMAPEV (SEQ ID NO:027), YIAPEV (SEQ ID NO:028), KAPEPL (SEQ ID NO:029), WMAPET (SEQ ID NO:031), EAPEDL (SEQ ID NO:032), DVAPED (SEQ ID NO:033), YLAPEV (SEQ ID NO:034), YMAPEH (SEQ ID NO:035), WTAPEA (SEQ ID NO:037), WYAPEC (SEQ ID NO:038), YRAPEI (SEQ ID NO:040), and LIAPEA (SEQ ID NO:061). These peptides are designated as peptides of group (1-S).

[0025] In one embodiment of the peptide of the core sequence (1), the NF κB repressor peptide is selected from peptides of a maximum length of twenty amino acid residues, comprising the following sequence:

[0026] YMAPEV (SEQ ID NO:001), IIAPEG (SEQ ID NO:002), TWAPES (SEQ ID NO:016), AWAPEA (SEQ ID NO:024), PSAPEN (SEQ ID NO:026), HMAPEV (SEQ ID NO:027), YIAPEV (SEQ ID NO:028), KAPEPL (SEQ ID NO:029), WMAPET (SEQ ID NO:031), EAPEDL (SEQ ID NO:032), DVAPED (SEQ ID NO:033), YLAPEV (SEQ ID NO:034), YMAPEH (SEQ ID NO:035), WTAPEA (SEQ ID NO:037), WYAPEC (SEQ ID NO:038), and YRAPEI (SEQ ID NO:040), provided that they do not include peptides containing the sequence LIAEAK (SEQ ID NO:009), peptides containing the sequence LIANAK (SEQ ID NO:012), and peptides containing SEQ ID NO:040. Peptides of NOS:041-113. These peptides are designated as peptides of the (1-T) group.

[0027] In one embodiment of the peptide of the core sequence (1), the NF κB repressor peptide is selected from the following peptide sequences:

[0028] YMAPEV (SEQ ID NO:001), IIAPEG (SEQ ID NO:002), TWAPES (SEQ ID NO:016), AWAPEA (SEQ ID NO:024), PSAPEN (SEQ ID NO:026), HMAPEV (SEQ ID NO:027), YIAPEV (SEQ ID NO:028), KAPEPL (SEQ ID NO:029), WMAPET (SEQ ID NO:031), EAPEDL (SEQ ID NO:032), DVAPED (SEQ ID NO:033), YLAPEV (SEQ ID NO:034), YMAPEH (SEQ ID NO:035), WTAPEA (SEQ ID NO:037), WYAPEC (SEQ ID NO:038), YRAPEI (SEQ ID NO:040), and LIAPEA (SEQ ID NO:061). These peptides are designated as peptides of group (1-V).

[0029] In any of the foregoing embodiments, the length of the peptide may be four to fifteen amino acids, four to twelve amino acids, four to ten amino acids, four to eight amino acids, six to twenty amino acids, six to fifteen amino acids, six to twelve amino acids, six to ten amino acids, or six to eight amino acids. Any of the foregoing embodiments may not include peptides containing the sequence LWAEAK (SEQ ID NO:008), peptides containing the sequence LIAEAK (SEQ ID NO:009), peptides containing the sequence LVAEAK (SEQ ID NO:030), peptides containing the sequence LIANAK (SEQ ID NO:012), and peptides containing EQ ID NOS:041-113.

[0030] In one embodiment of the peptide of the core sequence (1), the NF κB repressor peptide is selected from the following peptide sequences:

[0031] YMAPEV (SEQ ID NO:001), IIAPEG (SEQ ID NO:002), TWAPES (SEQ ID NO:016), AWAPEA (SEQ ID NO:024), PSAPEN (SEQ ID NO:026), HMAPEV (SEQ ID NO:027), YIAPEV (SEQ ID NO:028), KAPEPL (SEQ ID NO:029), WMAPET (SEQ ID NO:031), EAPEDL (SEQ ID NO:032), DVAPED (SEQ ID NO:033), YLAPEV (SEQ ID NO:034), YMAPEH (SEQ ID NO:035), WTAPEA (SEQ ID NO:037), WYAPEC (SEQ ID NO:038), and YRAPEI (SEQ ID NO:040). These peptides are designated as peptides in group (1-W).

[0032] In one embodiment, the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0033] Xxx-Ala-Pro-D-Glu

[0034] Where Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, Phe, 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (2). NF κB repressive peptides containing the core sequence (2) and having a length of four to twenty amino acid residues are designated as peptides of the core sequence (2). In another embodiment, the peptide of the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include a peptide containing the sequence LWAEAK (SEQ ID NO:008), a peptide containing the sequence LIAEAK (SEQ ID NO:009), a peptide containing the sequence LVAEAK (SEQ ID NO:030), a peptide containing the sequence LIANAK (SEQ ID NO:012), or a peptide containing EQ ID NOS:041-113.

[0035] In one embodiment of the peptide of the core sequence (2), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0036] Xxx-Ala-Pro-D-Glu

[0037] Wherein Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, or Phe. The peptide motif is designated as the core sequence (2-N). An NF κB repressor peptide containing the core sequence (2-N) and having a length of four to twenty amino acid residues is designated as the peptide containing the core sequence (2-N). In another embodiment, the peptide of this motif does not include peptides containing the sequence LIAPEA (SEQ ID NO: 061) and does not include peptides containing the sequence LWAEAK (SEQ ID NO: 008), LIAEAK (SEQ ID NO: 009), LVAEAK (SEQ ID NO: 030), LIANAK (SEQ ID NO: 012), or EQ ID NOS: 041-113.

[0038] In one embodiment of the peptide of the core sequence (2), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0039] Xxx-Ala-Pro-D-Glu

[0040] Where Xxx is selected from 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (2-U). NF κB repressive peptides containing the core sequence (2-U) and having a length of four to twenty amino acid residues are designated as peptides with the core sequence (2-U). In another embodiment, the peptide of the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include a peptide containing the sequence LWAEAK (SEQ ID NO:008), a peptide containing the sequence LIAEAK (SEQ ID NO:009), a peptide containing the sequence LVAEAK (SEQ ID NO:030), a peptide containing the sequence LIANAK (SEQ ID NO:012), or a peptide containing EQ ID NOS:041-113.

[0041] In one embodiment of the peptide of core sequence (2), the NF κB inhibitory peptide is selected from peptides of up to twenty amino acid residues in length, comprising the following sequences: LFAP[D]EA (SEQ ID NO:013), LIAP[D]EA (SEQ ID NO:014), or AWAP[D]EA (SEQ ID NO:025). These peptides are designated as peptides of group (2-S).

[0042] In one embodiment of the peptide of core sequence (2), the NFκB repressive peptide is selected from peptides of a maximum length of twenty amino acid residues, comprising the sequences LFAP[D]EA (SEQ ID NO:013), LIAP[D]EA (SEQ ID NO:014), or AWAP[D]EA (SEQ ID NO:025), provided that peptides comprising the sequence LIAEAK (SEQ ID NO:009), peptides comprising the sequence LIANAK (SEQ ID NO:012), and peptides comprising SEQ ID NOS:041-113 are excluded. These peptides are designated as peptides of group (2-T).

[0043] In any of the foregoing embodiments, the length of the peptide may be four to fifteen amino acids, four to twelve amino acids, four to ten amino acids, four to eight amino acids, six to twenty amino acids, six to fifteen amino acids, six to twelve amino acids, six to ten amino acids, or six to eight amino acids. Any of the foregoing embodiments may not include peptides containing the sequence LWAEAK (SEQ ID NO:008), peptides containing the sequence LIAEAK (SEQ ID NO:009), peptides containing the sequence LVAEAK (SEQ ID NO:030), peptides containing the sequence LIANAK (SEQ ID NO:012), and peptides containing EQ ID NOS:041-113.

[0044] In one embodiment of the peptide of core sequence (2), the NF κB inhibitory peptide is selected from the following peptide sequences: LFAP[D]EA (SEQ ID NO:013), LIAP[D]EA (SEQ ID NO:014), or AWAP[D]EA (SEQ ID NO:025). These peptides are designated as peptides of group (2-V).

[0045] In one embodiment, the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0046] Xxx-Ala-Glu-Ala

[0047] Wherein Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, Phe, 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (3). In another embodiment, the peptide of this motif does not include a peptide containing the sequence LIAEAK (SEQ ID NO:009). In another embodiment, the peptide of the motif does not include the peptide containing the sequence LIAPEA (SEQ ID NO: 061) and does not include the peptide containing the sequence LWAEAK (SEQ ID NO: 008), the peptide containing the sequence LIAEAK (SEQ ID NO: 009), the peptide containing the sequence LVAEAK (SEQ ID NO: 030), the peptide containing the sequence LIANAK (SEQ ID NO: 012), or the peptide containing EQ ID NOS: 041-113. An NF κB repressive peptide containing a core sequence (3) of four to twenty amino acid residues in length is designated as the peptide of the core sequence (3).

[0048] In one embodiment of the peptide of the core sequence (3), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0049] Xxx-Ala-Glu-Ala

[0050] Wherein Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, or Phe. The peptide motif is designated as the core sequence (3-N). An NF κB repressor peptide containing the core sequence (3-N) and having a length of four to twenty amino acid residues is designated as a peptide containing the core sequence (3-N). In another embodiment, the peptide containing the core sequence (3-N) does not include a peptide containing the sequence LIAEAK (SEQ ID NO:009). In another embodiment, the peptide containing the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include peptides containing the sequence LWAEAK (SEQ ID NO:008), peptides containing the sequence LIAEAK (SEQ ID NO:009), peptides containing the sequence LVAEAK (SEQ ID NO:030), peptides containing the sequence LIANAK (SEQ ID NO:012), or peptides containing EQ ID NOS:041-113.

[0051] In one embodiment of the peptide of the core sequence (3), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0052] Xxx-Ala-Glu-Ala

[0053] Wherein Xxx is selected from 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (3-U). NF κB repressive peptides containing the core sequence (3-U) and having a length of four to twenty amino acid residues are designated as peptides containing the core sequence (3-U). In another embodiment, the peptide containing the core sequence (3-U) does not include peptides containing the sequence LIAEAK (SEQ ID NO:009). In another embodiment, the peptide of the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include a peptide containing the sequence LWAEAK (SEQ ID NO:008), a peptide containing the sequence LIAEAK (SEQ ID NO:009), a peptide containing the sequence LVAEAK (SEQ ID NO:030), a peptide containing the sequence LIANAK (SEQ ID NO:012), or a peptide containing EQ ID NOS:041-113.

[0054] In one embodiment of the peptide of core sequence (3), the NF κB inhibitory peptide is selected from peptides of up to twenty amino acid residues in length, having the following sequences: EIAEAL (SEQ ID NO:003), SNVAEA (SEQ ID NO:004), ANIAEA (SEQ ID NO:005), LWAEAK (SEQ ID NO:008), LIAEAK (SEQ ID NO:009), LVAEAH (SEQ ID NO:011), Sar-Trp-Ala-Glu-Ala-NMeAl (SEQ ID NO:018), AWAEAK (SEQ ID NO:020), LVAEAK (SEQ ID NO:030), or SNVAEA (SEQ ID NO:039). These peptides are designated as peptides of group (3-S).

[0055] In another embodiment of the peptide of core sequence (3), the NF κB inhibitory peptide is selected from peptides of up to twenty amino acid residues in length, comprising the following sequences: EIAEAL (SEQ ID NO:003), SNVAEA (SEQ ID NO:004), ANIAEA (SEQ ID NO:005), LWAEAK (SEQ ID NO:008), LVAEAH (SEQ ID NO:011), Sar-Trp-Ala-Glu-Ala-NMeAl (SEQ ID NO:018), AWAEAK (SEQ ID NO:020), LVAEAK (SEQ ID NO:030), or SNVAEA (SEQ ID NO:039), provided that peptides comprising the sequence LIAEAK (SEQ ID NO:009), LIANAK (SEQ ID NO:012), and SEQ ID NOS:041-113 are not included. These peptides are designated as peptides of group (3-T).

[0056] In any of the foregoing embodiments, the length of the peptide may be four to fifteen amino acids, four to twelve amino acids, four to ten amino acids, four to eight amino acids, six to twenty amino acids, six to fifteen amino acids, six to twelve amino acids, six to ten amino acids, or six to eight amino acids. Any of the foregoing embodiments may not include peptides containing the sequence LWAEAK (SEQ ID NO:008), peptides containing the sequence LIAEAK (SEQ ID NO:009), peptides containing the sequence LVAEAK (SEQ ID NO:030), peptides containing the sequence LIANAK (SEQ ID NO:012), and peptides containing EQ ID NOS:041-113.

[0057] In one embodiment of the peptide of core sequence (3), the NF κB inhibitory peptide is selected from the following peptide sequences: EIAEAL (SEQ ID NO:003), SNVAEA (SEQ ID NO:004), ANIAEA (SEQ ID NO:005), LWAEAK (SEQ ID NO:008), LIAEAK (SEQ ID NO:009), LVAEAH (SEQ ID NO:011), Sar-Trp-Ala-Glu-Ala-NMeAl (SEQ ID NO:018), AWAEAK (SEQ ID NO:020), LVAEAK (SEQ ID NO:030), or SNVAEA (SEQ ID NO:039). These peptides are designated as peptides of group (3-V).

[0058] In another embodiment of the peptide of core sequence (3), the NF κB inhibitory peptide is selected from the following peptide sequences: EIAEAL (SEQ ID NO:003), SNVAEA (SEQ ID NO:004), ANIAEA (SEQ ID NO:005), LWAEAK (SEQ ID NO:008), LVAEAH (SEQ ID NO:011), Sar-Trp-Ala-Glu-Ala-NMeAl (SEQ ID NO:018), AWAEAK (SEQ ID NO:020), LVAEAK (SEQ ID NO:030), or SNVAEA (SEQ ID NO:039). These peptides are designated as peptides of group (3-W).

[0059] In one embodiment, the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0060] Xxx-Ala-D-Glu-Ala

[0061] Where Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, Phe, 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (4). NF κB repressive peptides containing the core sequence (4) and having a length of four to twenty amino acid residues are designated as peptides of the core sequence (4). In another embodiment, the peptide of the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include a peptide containing the sequence LWAEAK (SEQ ID NO:008), a peptide containing the sequence LIAEAK (SEQ ID NO:009), a peptide containing the sequence LVAEAK (SEQ ID NO:030), a peptide containing the sequence LIANAK (SEQ ID NO:012), or a peptide containing EQ ID NOS:041-113.

[0062] In one embodiment of the peptide of the core sequence (4), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0063] Xxx-Ala-D-Glu-Ala

[0064] Wherein Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, or Phe. The peptide motif is designated as a core sequence (4-N). NF κB repressor peptides containing a core sequence (4-N) of four to twenty amino acid residues are designated as peptides containing the core sequence (4-N). In another embodiment, the peptide motif does not include peptides containing the sequence LIAPEA (SEQ ID NO: 061) and does not include peptides containing the sequence LWAEAK (SEQ ID NO: 008), LIAEAK (SEQ ID NO: 009), LVAEAK (SEQ ID NO: 030), LIANAK (SEQ ID NO: 012), or EQ ID NOS: 041-113.

[0065] In one embodiment of the peptide of the core sequence (4), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0066] Xxx-Ala-D-Glu-Ala

[0067] Where Xxx is selected from 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (4-U). NF κB repressive peptides containing a core sequence (4-U) of four to twenty amino acid residues are designated as peptides with a core sequence (4-U). In another embodiment, the peptide of the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include a peptide containing the sequence LWAEAK (SEQ ID NO:008), a peptide containing the sequence LIAEAK (SEQ ID NO:009), a peptide containing the sequence LVAEAK (SEQ ID NO:030), a peptide containing the sequence LIANAK (SEQ ID NO:012), or a peptide containing EQ ID NOS:041-113.

[0068] In one embodiment of the peptide of core sequence (4), the NF κB inhibitory peptide is selected from peptides of up to twenty amino acid residues in length, comprising the sequences Sar-Trp-Ala-[D]Glu-Ala-Sar (SEQ ID NO:019) or AWA[D]EAK (SEQ ID NO:021). These peptides are designated as peptides of group (4-S).

[0069] In one embodiment of the peptide of core sequence (4), the NF κB repressor peptide is selected from peptides of up to twenty amino acid residues in length, comprising the sequences Sar-Trp-Ala-[D]Glu-Ala-Sar (SEQ ID NO:019) or AWA[D]EAK (SEQ ID NO:021), provided that peptides comprising the sequence LIAEAK (SEQ ID NO:009), peptides comprising the sequence LIANAK (SEQ ID NO:012), and peptides comprising SEQ ID NOS:041-113 are not included. These peptides are designated as peptides of group (4-T).

[0070] In any of the foregoing embodiments, the length of the peptide may be four to fifteen amino acids, four to twelve amino acids, four to ten amino acids, four to eight amino acids, six to twenty amino acids, six to fifteen amino acids, six to twelve amino acids, six to ten amino acids, or six to eight amino acids. Any of the foregoing embodiments may not include peptides containing the sequence LWAEAK (SEQ ID NO:008), peptides containing the sequence LIAEAK (SEQ ID NO:009), peptides containing the sequence LVAEAK (SEQ ID NO:030), peptides containing the sequence LIANAK (SEQ ID NO:012), and peptides containing EQ ID NOS:041-113.

[0071] In one embodiment of the peptide of core sequence (4), the NF κB inhibitory peptide is selected from the following peptide sequences: Sar-Trp-Ala-[D]Glu-Ala-Sar (SEQ ID NO:019) or AWA[D]EAK (SEQ ID NO:021). These peptides are designated as peptides of group (4-V).

[0072] In one embodiment, the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0073] Xxx-Ala-Asn-Ala

[0074] Wherein Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, Phe, 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (5). An NF κB repressor peptide containing the core sequence (5) and having a length of four to twenty amino acid residues is designated as the peptide of the core sequence (5). In another embodiment, the peptide of the core sequence (5) does not include the peptide containing the sequence LIANAK (SEQ ID NO:012). In another embodiment, the peptide of the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include a peptide containing the sequence LWAEAK (SEQ ID NO:008), a peptide containing the sequence LIAEAK (SEQ ID NO:009), a peptide containing the sequence LVAEAK (SEQ ID NO:030), a peptide containing the sequence LIANAK (SEQ ID NO:012), or a peptide containing EQ ID NOS:041-113.

[0075] In one embodiment of the peptide of the core sequence (5), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0076] Xxx-Ala-Asn-Ala

[0077] Wherein Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, or Phe. The peptide motif is designated as the core sequence (5-N). An NF κB repressor peptide containing the core sequence (5-N) and having a length of four to twenty amino acid residues is designated as the peptide containing the core sequence (5-N). In another embodiment, the peptide containing the core sequence (5-N) does not include a peptide containing the sequence LIANAK (SEQ ID NO: 012). In another embodiment, the peptide containing the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO: 061) and does not include peptides containing the sequence LWAEAK (SEQ ID NO: 008), peptides containing the sequence LIAEAK (SEQ ID NO: 009), peptides containing the sequence LVAEAK (SEQ ID NO: 030), peptides containing the sequence LIANAK (SEQ ID NO: 012), or peptides containing EQ ID NOS: 041-113.

[0078] In one embodiment of the peptide of the core sequence (5), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0079] Xxx-Ala-Asn-Ala

[0080] Wherein Xxx is selected from 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (5-U). NF κB repressive peptides containing the core sequence (5-U) and having a length of four to twenty amino acid residues are designated as peptides containing the core sequence (5-U). In another embodiment, the peptide containing the core sequence (5-U) does not include peptides containing the sequence LIANAK (SEQ ID NO: 012). In another embodiment, the peptide of the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include a peptide containing the sequence LWAEAK (SEQ ID NO:008), a peptide containing the sequence LIAEAK (SEQ ID NO:009), a peptide containing the sequence LVAEAK (SEQ ID NO:030), a peptide containing the sequence LIANAK (SEQ ID NO:012), or a peptide containing EQ ID NOS:041-113.

[0081] In one embodiment of the peptide of core sequence (5), the NF κB inhibitory peptide is selected from peptides of up to twenty amino acid residues in length, comprising the sequences LIANAK (SEQ ID NO:012) or AWANAK (SEQ ID NO:022). These peptides are designated as peptides of group (5-S).

[0082] In one embodiment of the peptide of core sequence (5), the NF κB repressor peptide is selected from peptides of a maximum length of twenty amino acid residues, comprising the sequence AWANAK (SEQ ID NO:022), provided that peptides comprising the sequence LIAEAK (SEQ ID NO:009), LIANAK (SEQ ID NO:012), and SEQ ID NOS:041-113 are not included. These peptides are designated as peptides of group (5-T).

[0083] In any of the foregoing embodiments, the length of the peptide may be four to fifteen amino acids, four to twelve amino acids, four to ten amino acids, four to eight amino acids, six to twenty amino acids, six to fifteen amino acids, six to twelve amino acids, six to ten amino acids, or six to eight amino acids. Any of the foregoing embodiments may not include peptides containing the sequence LWAEAK (SEQ ID NO:008), peptides containing the sequence LIAEAK (SEQ ID NO:009), peptides containing the sequence LVAEAK (SEQ ID NO:030), peptides containing the sequence LIANAK (SEQ ID NO:012), and peptides containing EQ ID NOS:041-113.

[0084] In one embodiment of the peptide of core sequence (5), the NF κB inhibitory peptide is selected from the following peptide sequences: LIANAK (SEQ ID NO:012) or AWANAK (SEQ ID NO:022). These peptides are designated as peptides of group (5-V).

[0085] In one embodiment of the peptide of core sequence (5), the NF κB inhibitory peptide is selected from the following peptide sequence: AWANAK (SEQ ID NO:022). This peptide is designated as a peptide of group (5-W).

[0086] In one embodiment, the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0087] Xxx-Ala-D-Asn-Ala

[0088] Where Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, Phe, 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (6). NF κB repressive peptides containing the core sequence (6) and having a length of four to twenty amino acid residues are designated as peptides containing the core sequence (6). In another embodiment, the peptide of the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include a peptide containing the sequence LWAEAK (SEQ ID NO:008), a peptide containing the sequence LIAEAK (SEQ ID NO:009), a peptide containing the sequence LVAEAK (SEQ ID NO:030), a peptide containing the sequence LIANAK (SEQ ID NO:012), or a peptide containing EQ ID NOS:041-113.

[0089] In one embodiment of the peptide of the core sequence (6), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0090] Xxx-Ala-D-Asn-Ala

[0091] Wherein Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, or Phe. The peptide motif is designated as the core sequence (6-N). An NF κB repressor peptide containing the core sequence (6-N) and having a length of four to twenty amino acid residues is designated as the peptide containing the core sequence (6-N). In another embodiment, the peptide of this motif does not include peptides containing the sequence LIAPEA (SEQ ID NO: 061) and does not include peptides containing the sequence LWAEAK (SEQ ID NO: 008), LIAEAK (SEQ ID NO: 009), LVAEAK (SEQ ID NO: 030), LIANAK (SEQ ID NO: 012), or EQ ID NOS: 041-113.

[0092] In one embodiment of the peptide of the core sequence (6), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0093] Xxx-Ala-D-Asn-Ala

[0094] Where Xxx is selected from 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (6-U). An NF κB repressive peptide containing a core sequence (5) of four to twenty amino acid residues is designated as the peptide core sequence (6-U). In another embodiment, the peptide of the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include a peptide containing the sequence LWAEAK (SEQ ID NO:008), a peptide containing the sequence LIAEAK (SEQ ID NO:009), a peptide containing the sequence LVAEAK (SEQ ID NO:030), a peptide containing the sequence LIANAK (SEQ ID NO:012), or a peptide containing EQ ID NOS:041-113.

[0095] In one embodiment of the peptide of the core sequence (6), the NF κB inhibitory peptide is selected from peptides of up to twenty amino acid residues in length, comprising the sequence AWA[D]NAK (SEQ ID NO:023). These peptides are designated as peptides of group (6-S).

[0096] In one embodiment of the peptide of core sequence (6), the NF κB repressor peptide is selected from peptides of a maximum length of twenty amino acid residues, comprising the sequence AWA[D]NAK (SEQ ID NO:023), provided that peptides comprising the sequence LIAEAK (SEQ ID NO:009), LIANAK (SEQ ID NO:012), and SEQ ID NOS:041-113 are not included. These peptides are designated as peptides of group (6-T).

[0097] In any of the foregoing embodiments, the length of the peptide may be four to fifteen amino acids, four to twelve amino acids, four to ten amino acids, four to eight amino acids, six to twenty amino acids, six to fifteen amino acids, six to twelve amino acids, six to ten amino acids, or six to eight amino acids. Any of the foregoing embodiments may not include peptides containing the sequence LWAEAK (SEQ ID NO:008), peptides containing the sequence LIAEAK (SEQ ID NO:009), peptides containing the sequence LVAEAK (SEQ ID NO:030), peptides containing the sequence LIANAK (SEQ ID NO:012), and peptides containing EQ ID NOS:041-113.

[0098] In one embodiment of the peptide of core sequence (6), the NF κB inhibitory peptide is selected from peptides with the following sequence: AWA[D]NAK (SEQ ID NO:023). This peptide is designated as a peptide of group (6-V).

[0099] In one embodiment, the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0100] Xxx-Ala-Glu-Asn

[0101] Wherein Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, Phe, 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (7). An NF κB repressor peptide containing the core sequence (7) and having a length of four to twenty amino acid residues is designated as the peptide of the core sequence (7). In another embodiment, the peptide of the core sequence (7) does not include the peptide containing the sequence ANVAENA (SEQ ID NO:042). In another embodiment, the peptide of the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include a peptide containing the sequence LWAEAK (SEQ ID NO:008), a peptide containing the sequence LIAEAK (SEQ ID NO:009), a peptide containing the sequence LVAEAK (SEQ ID NO:030), a peptide containing the sequence LIANAK (SEQ ID NO:012), or a peptide containing EQ ID NOS:041-113.

[0102] In one embodiment of the peptide of the core sequence (7), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0103] Xxx-Ala-Glu-Asn

[0104] Wherein Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, or Phe. The peptide motif is designated as the core sequence (7-N). An NF κB repressor peptide containing the core sequence (7-N) and having a length of four to twenty amino acid residues is designated as a peptide containing the core sequence (7-N). In another embodiment, the peptide containing the core sequence (7-N) does not include a peptide containing the sequence ANVAENA (SEQ ID NO: 042). In another embodiment, the peptide containing the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO: 061) and does not include peptides containing the sequence LWAEAK (SEQ ID NO: 008), LIAEAK (SEQ ID NO: 009), LVAEAK (SEQ ID NO: 030), LIANAK (SEQ ID NO: 012), or EQ ID NOS: 041-113.

[0105] In one embodiment of the peptide of the core sequence (7), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0106] Xxx-Ala-Glu-Asn

[0107] Where Xxx is selected from 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (7-U). NF κB repressive peptides containing a core sequence (7-U) of four to twenty amino acid residues are designated as peptides with a core sequence (7-U). In another embodiment, the peptide of the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include a peptide containing the sequence LWAEAK (SEQ ID NO:008), a peptide containing the sequence LIAEAK (SEQ ID NO:009), a peptide containing the sequence LVAEAK (SEQ ID NO:030), a peptide containing the sequence LIANAK (SEQ ID NO:012), or a peptide containing EQ ID NOS:041-113.

[0108] In one embodiment of the peptide of the core sequence (7), the NF κB repressor peptide is selected from peptides containing a length of four to twenty amino acid residues, namely NVAENA (SEQ ID NO:010) or ANVAENA (SEQ ID NO:042). These peptides are designated as peptides of group (7-S).

[0109] In one embodiment of the peptide of core sequence (7), the NF κB repressor peptide is selected from peptides comprising four to twenty amino acid residues in length, including the sequence NVAENA (SEQ ID NO:010), provided that peptides comprising the sequence LIAEAK (SEQ ID NO:009), peptides comprising the sequence LIANAK (SEQ ID NO:012), and peptides comprising SEQ ID NOS:041-113 are excluded. These peptides are designated as peptides of group (7-T).

[0110] In any of the foregoing embodiments, the length of the peptide may be four to fifteen amino acids, four to twelve amino acids, four to ten amino acids, four to eight amino acids, six to twenty amino acids, six to fifteen amino acids, six to twelve amino acids, six to ten amino acids, or six to eight amino acids. Any of the foregoing embodiments may not include peptides containing the sequence LWAEAK (SEQ ID NO:008), peptides containing the sequence LIAEAK (SEQ ID NO:009), peptides containing the sequence LVAEAK (SEQ ID NO:030), peptides containing the sequence LIANAK (SEQ ID NO:012), and peptides containing EQ ID NOS:041-113.

[0111] In one embodiment of the peptide of the core sequence (7), the NF κB inhibitory peptide is selected from the following peptide sequences: NVAENA (SEQ ID NO:010) or ANVAENA (SEQ ID NO:042). These peptides are designated as peptides of group (7-V).

[0112] In one embodiment of the peptide in the core sequence (7), the NF κB repressor peptide is NVAENA (SEQ ID NO:010). This peptide is designated as a peptide of group (7-W).

[0113] In one embodiment, the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0114] Xxx-Ala-D-Glu-Asn

[0115] Where Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, Phe, 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (8). NF κB repressive peptides containing the core sequence (8) and having a length of four to twenty amino acid residues are designated as peptides containing the core sequence (8). In another embodiment, the peptide of the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include a peptide containing the sequence LWAEAK (SEQ ID NO:008), a peptide containing the sequence LIAEAK (SEQ ID NO:009), a peptide containing the sequence LVAEAK (SEQ ID NO:030), a peptide containing the sequence LIANAK (SEQ ID NO:012), or a peptide containing EQ ID NOS:041-113.

[0116] In one embodiment of the peptide of the core sequence (8), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0117] Xxx-Ala-D-Glu-Asn

[0118] Wherein Xxx is selected from Met, Ile, Val, Cys, Trp, Tyr, or Phe. The peptide motif is designated as the core sequence (8-N). An NF κB repressor peptide containing the core sequence (8-N) and having a length of four to twenty amino acid residues is designated as the peptide containing the core sequence (8-N). In another embodiment, the peptide of this motif does not include peptides containing the sequence LIAPEA (SEQ ID NO:061) and does not include peptides containing the sequence LWAEAK (SEQ ID NO:008), LIAEAK (SEQ ID NO:009), LVAEAK (SEQ ID NO:030), LIANAK (SEQ ID NO:012), or EQ ID NOS:041-113.

[0119] In one embodiment of the peptide of the core sequence (8), the NF κB repressor peptide is selected from peptides of four to twenty amino acid residues in length, comprising the following sequence:

[0120] Xxx-Ala-D-Glu-Asn

[0121] Where Xxx is selected from 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthylpropionic acid, β-cyclohexyl-Ala, dehydroalanine, and β-tert-butyl-Ala. This peptide motif is designated as the core sequence (8-U). NF κB repressive peptides containing the core sequence (8) and having a length of four to twenty amino acid residues are designated as peptides with the core sequence (8-U). In another embodiment, the peptide of the motif does not include a peptide containing the sequence LIAPEA (SEQ ID NO:061) and does not include a peptide containing the sequence LWAEAK (SEQ ID NO:008), a peptide containing the sequence LIAEAK (SEQ ID NO:009), a peptide containing the sequence LVAEAK (SEQ ID NO:030), a peptide containing the sequence LIANAK (SEQ ID NO:012), or a peptide containing EQ ID NOS:041-113.

[0122] In one embodiment of the peptide of the core sequence (8), the NF κB inhibitory peptide is selected from peptides containing a length of four to twenty amino acid residues, namely NVA[D]ENA (SEQ ID NO:114) or ANVA[D]ENA (SEQ ID NO:115). These peptides are designated as peptides of the (8-S) group.

[0123] In one embodiment of the peptide of core sequence (8), the NF κB repressor peptide is selected from peptides comprising four to twenty amino acid residues in length, including the sequences NVA[D]ENA (SEQ ID NO:114) or ANVA[D]ENA (SEQ ID NO:115), provided that peptides comprising the sequence LIAEAK (SEQ ID NO:009), peptides comprising the sequence LIANAK (SEQ ID NO:012), and peptides comprising SEQ ID NOS:041-113 are excluded. These peptides are designated as peptides of group (8-T).

[0124] In any of the foregoing embodiments, the length of the peptide may be four to fifteen amino acids, four to twelve amino acids, four to ten amino acids, four to eight amino acids, six to twenty amino acids, six to fifteen amino acids, six to twelve amino acids, six to ten amino acids, or six to eight amino acids. Any of the foregoing embodiments may not include peptides containing the sequence LWAEAK (SEQ ID NO:008), peptides containing the sequence LIAEAK (SEQ ID NO:009), peptides containing the sequence LVAEAK (SEQ ID NO:030), peptides containing the sequence LIANAK (SEQ ID NO:012), and peptides containing EQ ID NOS:041-113.

[0125] In one embodiment of the peptide of the core sequence (8), the NF κB inhibitory peptide is selected from the following peptide sequences: NVA[D]ENA (SEQ ID NO:114) or ANVA[D]ENA (SEQ ID NO:115). These peptides are designated as peptides of group (8-V).

[0126] In another implementation, any set of core sequences described in any part of this document, including (1), (1-N), (1-U), (1-S), (1-T), (1-V), (1-W), (2), (2-N), (2-U), (2-S), (2-T), (2-V), (3), (3-N), (3-U), (3-S), (3-T), (3-V), (3-W), (4), (4-N), (4-U), (4-S), (4-T), (4-V), and (4-W, core sequences ... Peptides containing the following sequences may include: (5) core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6) core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7) core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8) core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, or (8-V) group. Additional conditions specify that the sequence LWAEAK (SEQ ID NO) is excluded. Peptides containing the sequence LIAEAK (SEQ ID NO: 008); peptides containing the sequence LIAEAK (SEQ ID NO: 009); peptides containing the sequence LIANAK (SEQ ID NO: 012); peptides containing the sequence LVAEAK (SEQ ID NO: 030); peptides containing the sequence ANVAENA (SEQ ID NO: 042); peptides containing the sequence LIAEAK (SEQ ID NO: 009), peptides containing the sequence LIANAK (SEQ ID NO: 012), peptides containing the sequence ANVAENA (SEQ ID NO: 042); or peptides containing the sequence LWAEAK (SEQ ID NO: 008), peptides containing the sequence LIAEAK (SEQ ID NO: 009), peptides containing the sequence LIANAK (SEQ ID NO: 012), peptides containing the sequence LVAEAK (SEQ ID NO: 030), and peptides containing EQ ID. Peptide with NOS:041-113.

[0127] In another implementation, any set of core sequences described in any part of this document, including (1), (1-N), (1-U), (1-S), (1-T), (1-V), (1-W), (2), (2-N), (2-U), (2-S), (2-T), (2-V), (3), (3-N), (3-U), (3-S), (3-T), (3-V), (3-W), (4), (4-N), (4-U), (4-S), (4-T), (4-V), and (4-W, core sequences, are included. Peptides of sequence (5), core sequence (5-N), core sequence (5-U), group (5-S), group (5-T), group (5-V), group (5-W), core sequence (6), core sequence (6-N), core sequence (6-U), group (6-S), group (6-T), group (6-V), group (7), core sequence (7-N), core sequence (7-U), group (7-S), group (7-T), group (7-V), group (7-W), core sequence (8), core sequence (8-N), core sequence (8-U), group (8-S), group (8-T), or group (8-V) may include one or more peptides that do not include sequences comprising any combination of one or more of SEQ ID NOS:001-113, and further condition that at least one peptide sequence is retained in the formed set.

[0128] In the above sequence and any other sequence disclosed herein, methionine (Met) may be replaced with ortholeucine (Nor).

[0129] In any embodiment of the specific peptide sequence disclosed herein and the method of using the peptide sequence disclosed herein, homologous sequences having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% sequence homology may be used, provided that the core sequence is preserved.

[0130] In any embodiment of the specific peptide sequence disclosed herein and the methods of using the disclosed peptide sequence, substitution can be made in the non-core region of the sequence by replacing one, two, or three amino acids with similar amino acids. Thus, negatively charged amino acids can replace other negatively charged amino acids (Asp, Glu); positively charged amino acids can replace other positively charged amino acids (Lys, Arg, His); hydrophobic amino acids can replace other hydrophobic amino acids (Ala, Val, Ile, Leu, Met); hydrophilic amino acids can replace other hydrophilic amino acids (Ser, Thr) (Asn, Gln); aromatic amino acids can replace other aromatic amino acids (Phe, Tyr, Trp, His); and smaller amino acids can replace other smaller amino acids (Ala, Gly). Amino acid groups in parentheses indicate amino acids considered similar for the purpose of substitution.

[0131] In one embodiment, the present invention includes a method for inhibiting NFκB activation or activity in cells, tissues, or organs, comprising contacting the cells, tissues, or organs with a therapeutically effective amount of a compound that inhibits NFκB activation or activity.

[0132] In one embodiment, the invention includes a method for inhibiting NF-κB activation or activity in, for example, cells, tissues, organs, or organisms, comprising contacting the cells, tissues, or organs with an effective amount of a compound that inhibits NF-κB activation or activity. The effective amount may, for example, reduce NF-κB activity in cells, tissues, organs, or organisms by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% (as determined by any of the tests described herein) compared to a baseline level before contact. In one embodiment, an effective amount may reduce the phosphorylation of NF κB (e.g., phosphorylation of the p65 or p50 subunit) in, for example, cells, tissues, organs, or organisms by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% (as determined by any of the assays described herein) compared to baseline levels before exposure. In one embodiment, an effective amount may reduce the expression of NF κB in, for example, cells, tissues, organs, or organisms by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% compared to baseline levels before exposure. In another embodiment, the compound is a peptide.In a further embodiment, the compound is a peptide selected from the following: core sequence (1), core sequence (1-N), core sequence (1-U), (1-S) group, (1-T) group, (1-V) group, (1-W) group, core sequence (2), core sequence (2-N), core sequence (2-U), (2-S) group, (2-T) group, (2-V) group, core sequence (3), core sequence (3-N), core sequence (3-U), (3-S) group, (3-T) group, (3-V) group, (3-W) group, core sequence (4), core sequence (4-N), core sequence (4-U), (4-S) group, ( Group 4-T), Group 4-V, Core sequence (5), Core sequence (5-N), Core sequence (5-U), Group 5-S, Group 5-T, Group 5-V, ​​Group 5-W, Core sequence (6), Core sequence (6-N), Core sequence (6-U), Group 6-S, Group 6-T, Group 6-V, Core sequence (7), Core sequence (7-N), Core sequence (7-U), Group 7-S, Group 7-T, Group 7-V, Group 7-W, Core sequence (8), Core sequence (8-N), Core sequence (8-U), Group 8-S, Group 8-T, Group 8-V, SEQ Peptides of ID NOS:001-069, (SEQ ID NOS:001-008, 010, 011 and 013-040) and (SEQ ID NOS:001-007, 010, 011, 013-029 and 031-040).

[0133] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering a compound containing a therapeutically effective amount of a compound that inhibits the activation or activity of NF-κB. In another embodiment, the composition comprises a therapeutically effective amount of one or more peptides selected from the group consisting of: core sequence (1), core sequence (1-N), core sequence (1-U), group (1-S), group (1-T), group (1-V), group (1-W), core sequence (2), core sequence (2-N), core sequence (2-U), group (2-S), group (2-T), group (2-V), group (2-V), core sequence (3), core sequence (3-N), core sequence (3-U), group (3-S), group (3-T), group (3-V), group (3-W), core sequence (4), core sequence (4-N), core sequence (4-U), group (4-S). (4-T) group, (4-V) group, core sequence (5), core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6), core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7), core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8), core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, (8-V) group, SEQ Peptides of SEQ ID NOS: 001-069, (SEQ ID NOS: 001-007, 010, 011, 013-029 and 031-040), and (SEQ ID NOS: 001-007, 010, 011, 013-029 and 031-040). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is by topical application. In one embodiment, administration is by subcutaneous injection. In one embodiment, administration is by intravenous injection. In one embodiment, administration is by intravenous injection. In one embodiment, pain is related to wound healing. In one embodiment, pain does not include pain related to wound healing.

[0134] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (1). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0135] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (1-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0136] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (1-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0137] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (1-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0138] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (1-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0139] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (2). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0140] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (2-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0141] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (2-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0142] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (2-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0143] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (2-T) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0144] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (2-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0145] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (3). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0146] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (3-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0147] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (3-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0148] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0149] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-T) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0150] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0151] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-W) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0152] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (4). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0153] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (4-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0154] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (4-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0155] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (4-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0156] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (4-T) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0157] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (4-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0158] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (5). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0159] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (5-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0160] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (5-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0161] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0162] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-T) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0163] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0164] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-W) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0165] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (6). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0166] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (6-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0167] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (6-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0168] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (6-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0169] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (6-T) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0170] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (6-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0171] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (7). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0172] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (7-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0173] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (7-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0174] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0175] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-T) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0176] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0177] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-W) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0178] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (8). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0179] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (8-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0180] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (8-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0181] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (8-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0182] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (8-T) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0183] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (8-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0184] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from SEQ ID NOS: 001 to 040. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0185] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from SEQ ID NOS:001-008, 010, 011, and 013-040. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0186] In one embodiment, the invention includes a method of treating pain in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from SEQ ID NOS:041-069. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the pain is related to wound healing. In one embodiment, the pain does not include pain related to wound healing.

[0187] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering a compound containing a therapeutically effective amount of a compound that inhibits NF-κB activation or activity. In another embodiment, the composition comprises a therapeutically effective amount of one or more peptides selected from the group consisting of: core sequence (1), core sequence (1-N), core sequence (1-U), group (1-S), group (1-T), group (1-V), group (1-W), core sequence (2), core sequence (2-N), core sequence (2-U), group (2-S), group (2-T), group (2-V), group (2-V), core sequence (3), core sequence (3-N), core sequence (3-U), group (3-S), group (3-T), group (3-V), group (3-W), core sequence (4), core sequence (4-N), core sequence (4-U), group (4-S). (4-T) group, (4-V) group, core sequence (5), core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6), core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7), core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8), core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, (8-V) group, SEQ Peptides of SEQ ID NOS: 001-069, (SEQ ID NOS: 001-008, 010, 011 and 013-040) and (SEQ ID NOS: 001-007, 010, 011, 013-029 and 031-040). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is by topical application. In one embodiment, administration is by subcutaneous injection. In one embodiment, administration is by intravenous injection. In one embodiment, administration is by intravenous injection. In one embodiment, the inflammation is inflammation of the skin and dermis, inflammation of the eyes, or inflammation due to wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, inflammation of the eyes, or inflammation due to wound healing. In one embodiment, the inflammation is due to an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is bacteria, a virus, a fungus, or a parasite.In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0188] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (1). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0189] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (1-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0190] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (1-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0191] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (1-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0192] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (1-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0193] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (2). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0194] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (2-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0195] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (2-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0196] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (2-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0197] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (2-T) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0198] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (2-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0199] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (3). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0200] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (3-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0201] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (3-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0202] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0203] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-T) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0204] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0205] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-W) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0206] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (4). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0207] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (4-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0208] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (4-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0209] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (4-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0210] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (4-T) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0211] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (4-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0212] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (5). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0213] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (5-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0214] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (5-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0215] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0216] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-T) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0217] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0218] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-W) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0219] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (6). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0220] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (6-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0221] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (6-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing.

[0222] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (6-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0223] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (6-T) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0224] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (6-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0225] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (7). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0226] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (7-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0227] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (7-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0228] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0229] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-T) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0230] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0231] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-W) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0232] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (8). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0233] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (8-N). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0234] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (8-U). In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0235] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (8-S) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0236] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (8-T) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0237] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (8-V) group. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0238] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from SEQ ID NOS: 001 to 040. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0239] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from SEQ ID NOS:001-008, 010, 011, and 013-040. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one embodiment, the inflammation is caused by a neurodegenerative disease; in another embodiment, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0240] In one embodiment, the invention includes a method of treating inflammation in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from SEQ ID NOS:041-069. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection. In one embodiment, administration is an intravenous injection. In one embodiment, administration is an intravenous injection. In one embodiment, the inflammation is an inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation does not include inflammation of the skin and dermis, an inflammation of the eyes, or an inflammation resulting from wound healing. In one embodiment, the inflammation is caused by an autoimmune disease; in another embodiment, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, lupus, or amyotrophic lateral sclerosis (ALS). In one embodiment, the inflammation is caused by a gastrointestinal disease; in another embodiment, the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, or colitis. In one embodiment, the inflammation is caused by an infectious organism; in another embodiment, the infectious organism is a bacterium, virus, fungus, or parasite. In one implementation, the inflammation is caused by a neurodegenerative disease; in another implementation, the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, or stroke.

[0241] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering a compound containing a therapeutically effective amount of a compound that inhibits NF-κB activation or NF-κB activity. In another embodiment, the composition comprises a therapeutically effective amount of one or more peptides selected from the group consisting of: core sequence (1), core sequence (1-N), core sequence (1-U), group (1-S), group (1-T), group (1-V), group (1-W), core sequence (2), core sequence (2-N), core sequence (2-U), group (2-S), group (2-T), group (2-V), group (2-V), core sequence (3), core sequence (3-N), core sequence (3-U), group (3-S), group (3-T), group (3-V), group (3-W), core sequence (4), core sequence (4-N), core sequence (4-U), group (4-S). (4-T) group, (4-V) group, core sequence (5), core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6), core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7), core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8), core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, (8-V) group, SEQ Peptides of SEQ ID NOS: 001-069, (SEQ ID NOS: 001-008, 010, 011 and 013-040), and (SEQ ID NOS: 001-007, 010, 011, 013-029 and 031-040). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or oral administration. In one embodiment, administration is by topical application. In one embodiment, administration is by subcutaneous injection.

[0242] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (1). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0243] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (1-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0244] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (1-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0245] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (1-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0246] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (1-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0247] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (2). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0248] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (2-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0249] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (2-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0250] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (2-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0251] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (2-T) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0252] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (2-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection.

[0253] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (3). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0254] In one embodiment, the present invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (3-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0255] In one embodiment, the present invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (3-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0256] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection.

[0257] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-T) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0258] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0259] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-W) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0260] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (4). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0261] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (4-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0262] In one embodiment, the present invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (4-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0263] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (4-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0264] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (4-T) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0265] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (4-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0266] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (5). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0267] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (5-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0268] In one embodiment, the present invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (5-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0269] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0270] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-T) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0271] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0272] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-W) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0273] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (6). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0274] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (6-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0275] In one embodiment, the present invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (6-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0276] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (6-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection.

[0277] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (6-T) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0278] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (6-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection.

[0279] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (7). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0280] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (7-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0281] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (7-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0282] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0283] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-T) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0284] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection.

[0285] In one embodiment, the present invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-W) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0286] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (8). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0287] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (8-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0288] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (8-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0289] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (8-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0290] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (8-T) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0291] In one embodiment, the invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (8-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0292] In one embodiment, the present invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from SEQ ID NOS: 001 to 040. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0293] In one embodiment, the present invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from SEQ ID NOS:001-008, 010, 011, and 013-040. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a topical application. In one embodiment, administration is a subcutaneous injection.

[0294] In one embodiment, the present invention includes a method of treating oral mucositis in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from SEQ ID NOS:041-069. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0295] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering a compound containing a therapeutically effective amount of a compound that inhibits the activation or activity of NF-κB. In another embodiment, the composition comprises a therapeutically effective amount of one or more peptides selected from the group consisting of: core sequence (1), core sequence (1-N), core sequence (1-U), group (1-S), group (1-T), group (1-V), group (1-W), core sequence (2), core sequence (2-N), core sequence (2-U), group (2-S), group (2-T), group (2-V), group (2-V), core sequence (3), core sequence (3-N), core sequence (3-U), group (3-S), group (3-T), group (3-V), group (3-W), core sequence (4), core sequence (4-N), core sequence (4-U), group (4-S). (4-T) group, (4-V) group, core sequence (5), core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6), core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7), core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8), core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, (8-V) group, SEQ Peptides of SEQ ID NOS: 001-069, (SEQ ID NOS: 001-008, 010, 011 and 013-040), and (SEQ ID NOS: 001-007, 010, 011, 013-029 and 031-040). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or oral administration. In one embodiment, administration is by topical application. In one embodiment, administration is by subcutaneous injection.

[0296] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (1). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0297] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (1-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0298] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (1-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0299] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (1-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0300] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (1-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0301] In one embodiment, the invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (2). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0302] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (2-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0303] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (2-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0304] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (2-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0305] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (2-T) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0306] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (2-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0307] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (3). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0308] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (3-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0309] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (3-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0310] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0311] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-T) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0312] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0313] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (3-W) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0314] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (4). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0315] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (4-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0316] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (4-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0317] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (4-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0318] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (4-T) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0319] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (4-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0320] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (5). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0321] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (5-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0322] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (5-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0323] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0324] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-T) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0325] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0326] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (5-W) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0327] In one embodiment, the invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (6). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0328] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (6-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0329] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (6-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0330] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (6-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0331] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (6-T) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0332] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (6-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0333] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (7). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0334] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (7-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0335] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (7-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0336] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0337] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-T) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0338] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0339] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (7-W) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0340] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering a composition containing a therapeutically effective amount of a peptide comprising the sequence ANVAENA (SEQ ID NO: 042) of seven to twenty residues in length. In another embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering a composition containing a therapeutically effective amount of a peptide comprising the sequence ANVAENA (SEQ ID NO: 042) of seven to fifteen residues in length. In yet another embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering a composition containing a therapeutically effective amount of a peptide comprising the sequence ANVAENA (SEQ ID NO: 042) of seven to twelve residues in length. In yet another embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering a composition containing a therapeutically effective amount of a peptide comprising the sequence ANVAENA (SEQ ID NO: 042). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In yet another embodiment, administration is a subcutaneous injection.

[0341] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (8). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0342] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from a core sequence (8-N). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0343] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the core sequence (8-U). In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0344] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (8-S) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0345] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (8-T) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0346] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from the (8-V) group. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0347] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from SEQ ID NOS: 001 to 040. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0348] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from SEQ ID NOS:001-008, 010, 011, and 013-040. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0349] In one embodiment, the present invention includes a method of treating oral cancer in a patient in need, comprising administering to the patient a composition containing a therapeutically effective amount of one or more peptides selected from SEQ ID NOS:041-069. In one embodiment, the composition further comprises a drug carrier suitable for intraoral or supraoral administration. In one embodiment, administration is a local application. In one embodiment, administration is a subcutaneous injection.

[0350] In one embodiment, the invention includes a method of treating a disease or condition in a patient in need, comprising administering a compound containing a therapeutically effective amount of a compound that inhibits the activation or activity of NF-κB. In another embodiment, the composition comprises a therapeutically effective amount of one or more peptides selected from the group consisting of: core sequence (1), core sequence (1-N), core sequence (1-U), group (1-S), group (1-T), group (1-V), group (1-W), core sequence (2), core sequence (2-N), core sequence (2-U), group (2-S), group (2-T), group (2-V), group (2-V), core sequence (3), core sequence (3-N), core sequence (3-U), group (3-S), group (3-T), group (3-V), group (3-W), core sequence (4), core sequence (4-N), core sequence (4-U), group (4-S). (4-T) group, (4-V) group, core sequence (5), core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6), core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7), core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8), core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, (8-V) group, SEQ Peptides of ID NOS:001-069, (SEQ ID NOS:001-008, 010, 011 and 013-040) and (SEQ ID NOS:001-007, 010, 011, 013-029 and 031-040), wherein the disease or condition is selected from ischemic diseases. In another embodiment, the ischemic disease is myocardial infarction, acute heart failure, chronic heart failure, cerebral infarction or pulmonary embolism.

[0351] In one embodiment, the invention includes a method of treating a disease or condition in a patient in need, comprising administering a compound containing a therapeutically effective amount of a compound that inhibits the activation or activity of NF-κB. In another embodiment, the composition comprises a therapeutically effective amount of one or more peptides selected from the group consisting of: core sequence (1), core sequence (1-N), core sequence (1-U), group (1-S), group (1-T), group (1-V), group (1-W), core sequence (2), core sequence (2-N), core sequence (2-U), group (2-S), group (2-T), group (2-V), group (2-V), core sequence (3), core sequence (3-N), core sequence (3-U), group (3-S), group (3-T), group (3-V), group (3-W), core sequence (4), core sequence (4-N), core sequence (4-U), group (4-S). (4-T) group, (4-V) group, core sequence (5), core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6), core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7), core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8), core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, (8-V) group, SEQ Peptides of ID NOS:001-069, (SEQ ID NOS:001-008, 010, 011 and 013-040) and (SEQ ID NOS:001-007, 010, 011, 013-029 and 031-040), wherein the diseases or conditions are selected from mucosal and skin diseases. In another implementation, the disease or condition is erythema, ulceration, inflammation, necrosis, or erosive dysplasia of the mucosal skin surface, such as the oral cavity, nasal cavity, gastrointestinal tract and respiratory tract, vagina and bladder; mucositis, oral mucositis, denture stomatitis, oral lichen planus, oral ulcer, pemphigus, bullous pemphigoid, oral lichen planus, oral mucosal contact dermatitis, herpetic ulcer, thrush, gastrointestinal mucositis, esophageal mucositis, intestinal mucositis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, oral ulcer, pemphigus, bullous pemphigoid, oral lichen planus, oral mucosal contact dermatitis, herpetic ulcer, thrush, nasal mucosal diseases including sinusitis and rhinitis, interstitial cystitis, radiation cystitis, mucosal and skin complications of Behçet's syndrome, radiation-induced oral mucositis, radiation-induced esophagitis, radiation proctitis, or mucosal damage caused by endoscopic surgery.

[0352] In one embodiment, the invention includes a method of treating a disease or condition in a patient in need, comprising administering a compound containing a therapeutically effective amount of a compound that inhibits the activation or activity of NF-κB. In another embodiment, the composition comprises a therapeutically effective amount of one or more peptides selected from the group consisting of: core sequence (1), core sequence (1-N), core sequence (1-U), group (1-S), group (1-T), group (1-V), group (1-W), core sequence (2), core sequence (2-N), core sequence (2-U), group (2-S), group (2-T), group (2-V), group (2-V), core sequence (3), core sequence (3-N), core sequence (3-U), group (3-S), group (3-T), group (3-V), group (3-W), core sequence (4), core sequence (4-N), core sequence (4-U), group (4-S). (4-T) group, (4-V) group, core sequence (5), core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6), core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7), core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8), core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, (8-V) group, SEQ Peptides of ID NOS:001-069, (SEQ ID NOS:001-008, 010, 011 and 013-040) and (SEQ ID NOS:001-007, 010, 011, 013-029 and 031-040), wherein the disease or condition is selected from inflammatory diseases. In another embodiment, the disease or condition is acne, ankylosing spondylitis, Barrett's esophagus, chronic fatigue syndrome (CFS / CFIDS / ME), chronic Lyme disease (spirochete disease), Crohn's disease, diabetes, depression, dermatitis, fasciitis, fibromyalgia (FM), gastroesophageal reflux disease (GERD), gingivitis, Hashimoto's thyroiditis, hypertension, hyperthyroidism, hypothyroidism, irritable bowel syndrome (IBS), interstitial cystitis (IC), kidney stones, Syndrome, lupus, multiple chemical sensitivity (MCS), migraine, Morgellons' disease, multiple sclerosis, osteoarthritis, periodontitis, polymyalgia rheumatica, prostatitis, psoriasis, psoriatic arthritis, Raynaud's syndrome / phenomenon, reactive arthritis (Rett syndrome), restless legs syndrome, reflex sympathetic dystrophy (RSD), rheumatoid arthritis, sarcoidosis, scleroderma, sinusitis, seasonal affective disorder (SAD), Sjögren's syndrome, stomatitis, tendinitis, ulcerative colitis, urticaria, uveitis, or vertigo.

[0353] In one embodiment, the invention includes a method of treating a disease or condition in a patient in need, comprising administering a compound containing a therapeutically effective amount of a compound that inhibits the activation or activity of NF-κB. In another embodiment, the composition comprises a therapeutically effective amount of one or more peptides selected from the group consisting of: core sequence (1), core sequence (1-N), core sequence (1-U), group (1-S), group (1-T), group (1-V), group (1-W), core sequence (2), core sequence (2-N), core sequence (2-U), group (2-S), group (2-T), group (2-V), group (2-V), core sequence (3), core sequence (3-N), core sequence (3-U), group (3-S), group (3-T), group (3-V), group (3-W), core sequence (4), core sequence (4-N), core sequence (4-U), group (4-S). (4-T) group, (4-V) group, core sequence (5), core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6), core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7), core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8), core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, (8-V) group, SEQ Peptides of ID NOS:001-069, (SEQ ID NOS:001-008, 010, 011 and 013-040) and (SEQ ID NOS:001-007, 010, 011, 013-029 and 031-040), wherein the disease or condition is selected from fibrotic diseases and scar formation. In another embodiment, the disease or condition is fibrosis, scar formation after incision or surgery, scar formation after burns, or adhesions after incision or surgery.

[0354] In one embodiment, the invention includes a method of treating a disease or condition in a patient in need, comprising administering a compound containing a therapeutically effective amount of a compound that inhibits the activation or activity of NF-κB. In another embodiment, the composition comprises a therapeutically effective amount of one or more peptides selected from the group consisting of: core sequence (1), core sequence (1-N), core sequence (1-U), group (1-S), group (1-T), group (1-V), group (1-W), core sequence (2), core sequence (2-N), core sequence (2-U), group (2-S), group (2-T), group (2-V), group (2-V), core sequence (3), core sequence (3-N), core sequence (3-U), group (3-S), group (3-T), group (3-V), group (3-W), core sequence (4), core sequence (4-N), core sequence (4-U), group (4-S). (4-T) group, (4-V) group, core sequence (5), core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6), core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7), core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8), core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, (8-V) group, SEQ Peptides of ID NOS:001-069, (SEQ ID NOS:001-008, 010, 011 and 013-040) and (SEQ ID NOS:001-007, 010, 011, 013-029 and 031-040), wherein the disease or condition is selected from cancer. In another embodiment, cancer is lymphoproliferative disorders, lymphoma, leukemia, carcinoma, sarcoma, prostate cancer, breast cancer, cervical cancer, uterine cancer, endometrial cancer, bone cancer, stomach cancer, colon cancer, liver cancer, pancreatic cancer, various head and neck cancers, thyroid cancer, cancers of the central nervous system, cancers of the peripheral nervous system, brain cancer, kidney cancer, skin cancer, oral cancer, or oral tumors.

[0355] In one embodiment, the invention includes a method of treating a disease or condition in a patient in need, comprising administering a compound containing a therapeutically effective amount of a compound that inhibits the activation or activity of NF-κB. In another embodiment, the composition comprises a therapeutically effective amount of one or more peptides selected from the group consisting of: core sequence (1), core sequence (1-N), core sequence (1-U), group (1-S), group (1-T), group (1-V), group (1-W), core sequence (2), core sequence (2-N), core sequence (2-U), group (2-S), group (2-T), group (2-V), group (2-V), core sequence (3), core sequence (3-N), core sequence (3-U), group (3-S), group (3-T), group (3-V), group (3-W), core sequence (4), core sequence (4-N), core sequence (4-U), group (4-S). (4-T) group, (4-V) group, core sequence (5), core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6), core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7), core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8), core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, (8-V) group, SEQ Peptides of ID NOS:001-069, (SEQ ID NOS:001-008, 010, 011 and 013-040) and (SEQ ID NOS:001-007, 010, 011, 013-029 and 031-040), wherein the disease or condition is selected from age-related diseases or conditions.

[0356] In one embodiment, the invention includes a method of treating a disease or condition in a patient in need, comprising administering a compound containing a therapeutically effective amount of a compound that inhibits the activation or activity of NF-κB. In another embodiment, the composition comprises a therapeutically effective amount of one or more peptides selected from the group consisting of: core sequence (1), core sequence (1-N), core sequence (1-U), group (1-S), group (1-T), group (1-V), group (1-W), core sequence (2), core sequence (2-N), core sequence (2-U), group (2-S), group (2-T), group (2-V), group (2-V), core sequence (3), core sequence (3-N), core sequence (3-U), group (3-S), group (3-T), group (3-V), group (3-W), core sequence (4), core sequence (4-N), core sequence (4-U), group (4-S). (4-T) group, (4-V) group, core sequence (5), core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6), core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7), core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8), core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, (8-V) group, SEQ Peptides of ID NOS:001-069, (SEQ ID NOS:001-008, 010, 011 and 013-040) and (SEQ ID NOS:001-007, 010, 011, 013-029 and 031-040), wherein the diseases or conditions are selected from those related to skin aging.

[0357] In one embodiment, the invention includes a method of treating a disease or condition in a patient in need, comprising administering a compound containing a therapeutically effective amount of a compound that inhibits the activation or activity of NF-κB. In another embodiment, the composition comprises a therapeutically effective amount of one or more peptides selected from the group consisting of: core sequence (1), core sequence (1-N), core sequence (1-U), group (1-S), group (1-T), group (1-V), group (1-W), core sequence (2), core sequence (2-N), core sequence (2-U), group (2-S), group (2-T), group (2-V), group (2-V), core sequence (3), core sequence (3-N), core sequence (3-U), group (3-S), group (3-T), group (3-V), group (3-W), core sequence (4), core sequence (4-N), core sequence (4-U), group (4-S). (4-T) group, (4-V) group, core sequence (5), core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6), core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7), core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8), core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, (8-V) group, SEQ Peptides of ID NOS:001-069, (SEQ ID NOS:001-008, 010, 011 and 013-040) and (SEQ ID NOS:001-007, 010, 011, 013-029 and 031-040), wherein the disease or symptom is pain.

[0358] In one embodiment, the invention includes a method of treating a disease or condition in a patient in need, comprising administering a compound containing a therapeutically effective amount of a compound that inhibits the activation or activity of NF-κB. In another embodiment, the composition comprises a therapeutically effective amount of one or more peptides selected from the group consisting of: core sequence (1), core sequence (1-N), core sequence (1-U), group (1-S), group (1-T), group (1-V), group (1-W), core sequence (2), core sequence (2-N), core sequence (2-U), group (2-S), group (2-T), group (2-V), group (2-V), core sequence (3), core sequence (3-N), core sequence (3-U), group (3-S), group (3-T), group (3-V), group (3-W), core sequence (4), core sequence (4-N), core sequence (4-U), group (4-S). (4-T) group, (4-V) group, core sequence (5), core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6), core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7), core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8), core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, (8-V) group, SEQ Peptides of ID NOS:001-069, (SEQ ID NOS:001-008, 010, 011 and 013-040) and (SEQ ID NOS:001-007, 010, 011, 013-029 and 031-040), wherein the disease or condition is radiation injury or a sequela of radiation exposure. In one embodiment, sequelae of radiation exposure do not include mucositis.

[0359] In another embodiment, the invention includes compositions for treating any disease or condition disclosed herein, use of the compositions for treating any disease or condition disclosed herein, or use of the compositions for producing medicaments for treating any disease or condition disclosed herein, including administering a compound containing a therapeutically effective amount of a compound that inhibits the activation of NF-κB or inhibits NF-κB activity. In another embodiment, the composition comprises one or more peptides selected from the following: core sequence (1), core sequence (1-N), core sequence (1-U), (1-S) group, (1-T) group, (1-V) group, (1-W) group, core sequence (2), core sequence (2-N), core sequence (2-U), (2-S) group, (2-T) group, (2-V) group, core sequence (3), core sequence (3-N), core sequence (3-U), (3-S) group, (3-T) group, (3-V) group, (3-W) group, core sequence (4), core sequence (4-N), core sequence (4-U), (4-S) group, (4-W) group, (4-N) group, core sequence (4-U), (4-S) group, (4-W) group, (4-N) group, core sequence (4-U), (4-S) group, (4-W) group, (4-N) group, core sequence (4-U), (4-S) group, (4-W) group, core sequence ... core sequence (4-S) group, (4-W) group, core sequence (4-N) group, core sequence (4-U), core sequence (4-S) group, (4-W) group, core sequence (4 -T) group, (4-V) group, core sequence (5), core sequence (5-N), core sequence (5-U), (5-S) group, (5-T) group, (5-V) group, (5-W) group, core sequence (6), core sequence (6-N), core sequence (6-U), (6-S) group, (6-T) group, (6-V) group, core sequence (7), core sequence (7-N), core sequence (7-U), (7-S) group, (7-T) group, (7-V) group, (7-W) group, core sequence (8), core sequence (8-N), core sequence (8-U), (8-S) group, (8-T) group, (8-V) group, SEQ Peptides of ID NOS:001-069, (SEQ ID NOS:001-008, 010, 011 and 013-040) and (SEQ ID NOS:001-007, 010, 011, 013-029 and 031-040).

[0360] Some embodiments described herein use the terms "comprising" or "containing" for each component / element. In other embodiments, these components / elements may be described using the transitional phrase "consistently composed of (these components / elements)". Thus, for example, if a composition or method disclosed herein comprises A and B, then another embodiment of the composition or method "consistently composed of A and B" and another embodiment of the composition or method "composed of A and B" are also considered to be disclosed herein. Similarly, embodiments describing each component / element as "consistently composed of" or "composed of" may also be described as "comprising" or "containing" these components / elements. Finally, embodiments describing each component / element as "consistently composed of" may also be described as "composed of (these components / elements)", and embodiments describing each component / element as "composed of" may also be described as "consistently composed of (these components / elements)".

[0361] When a composition is described as "consisting substantially of (the listed components)", the composition comprises the expressly listed components and may contain other components, such as inert excipients or carriers, that substantially do not affect the treated condition. However, the composition does not contain any other components besides the expressly listed components that have a substantial effect on the treated condition; or, if the composition contains additional components besides the listed components that have a substantial effect on the treated condition, the composition does not contain additional components in concentrations or amounts sufficient to have a substantial effect on the treated condition. When a method is described as "consisting substantially of (the listed steps)", the method includes the listed steps and may include other steps that substantially do not affect the treated condition, but the method does not include any other steps besides the expressly listed steps that have a substantial effect on the treated condition.

[0362] The compositions and methods described herein, including any embodiments of the invention described herein, can be used alone or in combination with other compositions and methods.

[0363] Overview of the attached figures

[0364] Figure 1A A diagram illustrating the potential steps in the NF-κB activation pathway that can be inhibited by the disclosed peptides. The inhibited steps are represented by a circle pierced by a diagonal line. express:

[0365] Figure 1B This demonstrates a positive feedback loop for TNF-α activation of NF-κB.

[0366] Figure 2The inhibitory effects of several disclosed peptides on TNF-α-activated NF-κB were demonstrated.

[0367] Figure 3 The inhibitory effects of the disclosed peptides on TNF-α-induced NF-κB activation and constitutive NF-κB activation were demonstrated. Firefly luciferase readings showed TNF-α-stimulated NF-κB levels, while Renella luciferase readings showed the level of constitutive NF-κB activation.

[0368] Figure 4 Western blots were created to show the activation and inhibition of p65 (NF κB) in SiHa cells. The disclosed peptides inhibit phosphorylation of the p65 subunit of NF κB. Peptide NP-1 is SEQ ID NO:008 (LWAEAK); peptide NP-2 is SEQ ID NO:015 (TNWAEN); peptide NP-3 is SEQ ID NO:016 (TWAPES); peptide NP-4 is SEQ ID NO:017 (TWSPEL).

[0369] Figure 5 shows the reduction of hamster cheek tumors induced by topical application of an NF-κB inhibitor peptide. Figure 5A Showing control animals. Figure 5B Induced tumors are shown on the cheeks of hamsters. Figure 5C The study showed that after six weeks of local application of the NF-κB inhibitor peptide ANVAENA (SEQ ID NO:042), the tumor shrank significantly.

[0370] Figure 6 shows a microscopic examination of a tumor generated by treatment with DMBA and then treated with the NF-κB inhibitor peptide NVAENA (SEQ ID NO:010) as shown in Figure 5. Figure 6A The untreated control tissue is shown. Figure 6B This shows tissue treated with DMBA (i.e., tumor tissue). Figure 6C The tissue treated with DMBA and then with the NF-κB inhibitor peptide, as shown in Figure 5, indicates that the histology after treatment is close to that of normal histology.

[0371] Figure 7 This study showcases different NF-κB target genes involved in various pathological processes, whose expression is associated with a wide range of diseases. It is anticipated that inhibiting these genes by suppressing NF-κB activation will contribute to the prevention and treatment of diseases caused by the overproduction of these genes and their products. These genes can be affected or downregulated by the NF-κB inhibitor peptide NVAENA (SEQ ID NO:010).

[0372] Figure 8A and Figure 8BThe disclosed peptides are shown for inhibiting NF κB activity. Figure 8A Showing SEQ IDS NOS:001 to 040. SEQ IDS NOS:009 and 012 are peptides disclosed in U.S. Patents 5,661,127, 5,780,436 and 6,638,912. Figure 8B The following peptides are shown in SEQ ID NOS: 041 to 069: 5,661,127, 5,780,436 and 6,638,912. Figure 8C The images show SEQ ID NOS:070 to 113, which are peptides disclosed in U.S. Patent Application Publication No. 2006 / 0293228.

[0373] Figure 9 shows amino acids and their abbreviations. Figure 9A The list includes the naturally occurring (protein) encoded amino acids. Figure 9B The list includes non-natural and / or non-coded (non-protein) amino acids.

[0374] Figure 10 The peptide ANVAENA (SEQ ID NO:042) was shown to improve hyperalgesia.

[0375] Figure 11 The effect of peptide ANVAENA (SEQ ID NO:042) on inflammation is shown. The light-colored (upper) curve represents the control group, and the dark-colored (lower) curve represents the peptide treatment.

[0376] Figure 12A and Figure 12B The effect of peptide LIANAK (SEQ ID NO:060, shown as “Leu-6 Lys” in the figure) on Smad2 phosphorylation is shown. Invention Details

[0378] This invention relates to the prevention or treatment of diseases and conditions involving disturbances in the normal homeostasis of the transcription factor NFκB.

[0379] The normal homeostasis of the transcription factor NF-κB is induced by more than 150 stimuli, including free radicals, exposure to ultraviolet radiation, ionizing radiation, inflammation, physical and chemical stress, infection, and injury. Currently used cytotoxic drugs can produce the undesirable side effect of inducing NF-κB activation, which can lead to inhibition of apoptosis and consequently tolerance to these drugs. Therefore, NF-κB inhibitory molecules may be clinically useful, whether as monotherapy or in combination with classic chemotherapeutic agents. "NF-κB activation" can refer to the nuclear translocation of NF-κB and / or subsequent regulation of genes directly or indirectly controlled by NF-κB binding sites. Functionally, NF-κB activation involves the binding of NF-κB to κB regulatory sequences in cellular DNA, thereby inducing transcription of operation-related genes (which may require other factors acting in conjunction with NF-κB to initiate transcription).

[0380] Active NF-κB is involved in the transcriptional regulation of more than 150 target genes. Because a wide variety of bacteria and viruses activate NF-κB, and because transcription factors regulate the expression of inflammatory cytokines, chemokines, immune receptors, and cell adhesion molecules, NF-κB is often referred to as a central mediator of the human immune response. Data collected suggest that NF-κB functions more broadly as a central regulator of the stress response. Furthermore, NF-κB activation blocks apoptosis in many cell types. Linking the stress response and anti-apoptotic pathways through a common transcription factor may lead to increased cell survival after stress stimulation.

[0381] NF-κB is a widely expressed transcription factor that controls the expression of a variety of genes involved in inflammation, immune response, lymphoid differentiation, growth control, and development. Most genes controlled by NF-κB are considered effectors of cellular stress and contribute to inflammation, apoptosis, and cell growth / expansion. The NF-κB and Wnt pathways are key components of the molecular pathology of mucositis. These pathways are the molecular targets of the peptides disclosed herein. The disclosed peptides are stereoconformities of certain common conformational epitopes naturally occurring in signaling enzymes, serine-threonine kinases, tyrosine kinases, and receptor kinases. The disclosed peptides mimic the structural features of these kinases and participate in their allosteric regulation. The disclosed peptides act as molecular decoys and influence the interactions between protein kinases and their substrates.

[0382] NF κB exists as homogeneous or heterodimers of five related proteins: p50, p52, p65(RelA), c-Rel, and RelB. The most common active dimers are the p50 / RelA or p52 / RelA heterodimers. The dimerized NF κB exists in the cytoplasm as part of an inactive complex with an inhibitory protein called IκB. IκB proteins p105, p100, IκBa, IκBb, IκBg, IκBe, IκBz, and Bcl-3 exhibit different affinities for each Rel / NF κB complex, their regulation differs slightly, and they are expressed in a tissue-specific manner. For NF κB to be activated, the inhibitory IκB protein must dissociate from the inactive complex. This is achieved through phosphorylation of IκB followed by ubiquitination and degradation in the proteasome. IκB is phosphorylated and degraded in response to various environmental stimuli, such as pro-inflammatory cytokines, viruses, lipopolysaccharides, oxidants, ultraviolet radiation, and ionizing radiation.

[0383] Most genes regulated by NF-κB transcription are involved in immune signaling and inflammatory responses. In fact, NF-κB transcriptional regulation of cytokine expression is perhaps one of the most important factors in assessing the role of NF-κB in pathological states. These cytokines include TNFα, IL-1α / β, IL-2, IL-3, IL-6, IL-12, GM-CSF, M-CSF, and G-CSF. NF-κB also regulates the expression of chemokines (MCP-1, KC, MIP-1, and various CCLs) and adhesion molecules (ICAM-1, E-selectin, and VCAM-1), which allow immune cells to recruit and attach to sites of inflammation. Furthermore, NF-κB upregulates the expression of receptors on immune cells (CD80 / 81, IL-2Rα chain, TLR-2) and proteins involved in antigen presentation (MHC class I and β2-microglobulin) to enable appropriate innate and adaptive immune responses. Recently, NF-κB has been shown to have anti-apoptotic effects in certain cell types, most likely through the induction of anti-apoptotic gene expression. This function can protect tumor cells from anti-cancer treatments and makes it possible to sensitize tumor cells with NF-κB inhibitory compounds to improve the efficacy of anti-cancer treatments.

[0384] Disruptions to the NF-κB and Wnt signaling pathways play a crucial role in disease. Signal transduction depends on protein phosphorylation catalyzed by serine-threonine and tyrosine kinases, collectively known as protein kinases. Protein kinases modify protein function by transferring phosphate groups from adenosine triphosphate (ATP) or guanosine triphosphate (GTP) to the free hydroxyl groups of the amino acids serine, threonine, and tyrosine. Protein kinases play a vital role in signal transduction cascades, from controlling cell differentiation, growth, and proliferation to initiating and regulating immune responses. Abnormal kinase activity is associated with an increasing number of diseases; currently, over 400 human diseases are indirectly or directly related to protein kinases. Therefore, protein kinases are considered very important drug targets.

[0385] The structures of tyrosine kinases and serine-threonine kinases are highly conserved. Serine-threonine kinases possess multiple interaction sites and play unique roles in intermolecular recognition, interaction and binding, and catalysis. Serine-threonine kinase activity is regulated by allosteric mechanisms. Allosteric regulators provide a mode of regulation that amplifies the spontaneous regulatory response rather than completely inhibiting or continuously activating the protein.

[0386] Peptides can mimic protein-protein interactions. They provide a powerful means of regulating signal transduction events. The disclosed peptides mimic protein domains involved in kinase interactions and participate in the allosteric regulation of these kinases. The disclosed peptides act as molecular decoys and influence the interactions between protein kinases and their substrates. The disclosed peptides are allosteric regulators. They function by inducing conformational changes and activating certain serine and threonine kinases through interaction with specific host sites. As conformational decoys, it is hypothesized that the disclosed peptides compete for interaction between certain key serine and threonine kinases and their substrates. The disclosed peptides disrupt the interaction between substrate binding and docking sites. The disclosed peptides block the interaction between IKK-2 and the IKK complex and interfere with the NEMO-IKK-2 interaction. The peptide inhibits IKK-2 phosphorylation. This leads to inhibition of phosphorylation of p65 and IκB inhibitors. These results are illustrated in Figures 1-4. Figure 1A A diagram illustrating the steps in the disclosed peptide inhibition of the NF-κB activation pathway is shown. Computer simulations demonstrate that the disclosed peptide can dock at certain serine and threonine kinase interaction sites, preventing enzyme-substrate interactions and inhibiting key enzymatic catalytic steps in the NF-κB activation pathway. These potentially inhibited pathways include... Figure 1A As shown, circles containing slashes represent potential steps that can be inhibited by peptides. In experiments, the observed inhibition manifested as a decrease in NF κB activation levels (see [link to documentation]). Figure 2 and Figure 3This includes decreased phosphorylation of the NF κB subunit (see Example 2). Based on these observations, the hypothesized overall mechanism of NF κB inhibition is schematically described. More than 150 stimuli can induce NF κB activation. The NF κB dimer exists in the cytoplasm as an inactive complex with the IKB protein, which must be phosphorylated by specific IKB kinases IKKα and IKKβ. IKKα and IKKβ are present in the inhibited complex and are activated by stimulus-induced kinases. Three of these kinases are shown in the figure: NIK, TAK1, and MEKK3. The disclosed peptides can act as substrate decoys and inhibit these kinases. The inhibitory sites are indicated by arrows. Figure 1A The abbreviations used are as follows: BAFFR: B cell activating factor receptor; CD40: CD40 antigen (TNF receptor superfamily member 5); IκB: B cell κ light chain peptide gene enhancer nuclear factor inhibitor β; IKKα: nuclear factor NF-κB inhibitor kinase α; IKKβ: nuclear factor NF-κB inhibitor kinase β; IKKγ: (NEMO) B cell κ light chain peptide gene enhancer inhibitor kinase γ; IRAK-1: interleukin-1 receptor-associated kinase 1; LTβR: lymphotoxin β receptor (TNFR superfamily member 3); MAPK: mitogen-activated protein kinase; NIK: NF-κB-induced kinase; P100: nuclear factor NF-κB BP100 subunit; p52: nuclear factor NF-κB P52 subunit; p65: nuclear factor NF-κB P65 subunit; RANK: NF-κB receptor activator; RelA: nuclear factor NF-κB P65 subunit; RELB: transcription factor RelB; TAK-1: TGF-β activated kinase 1; TLR: Toll-like receptor; TNF-α: tumor necrosis factor α.

[0387] Phosphorylation of the p65 NF-κB subunit provides a convenient assay for NF-κB activity. This assay is described in Moreno et al., Nucleic Acids Research, 38(18):6029–6044 (2010) and Wang et al., PLoS ONEVol.7, Issue 3, e34122 (2012). Cellular Activation of Signaling ELISA (CASE) can be used. TM The kit (available from SABiosciences Corporation, Frederick, Maryland) and NFkBp65 (Total / Phospho) InstantOne TMPhosphorylated NF-κB p65 was quantified using either an ELISA kit (available from eBioscience, San Diego, California) or an NF-κB p65 (total) ELISA kit (catalog number KHO0371) (Thermo Fisher Scientific, Waltham, Massachusetts). A decrease in the amount of phosphorylated NF-κB p65 indicates inhibition of NF-κB activity.

[0388] NF-κB activation induces nuclear translocations of transcription factors and their interaction with specific genomic sites, leading to the expression of disease-related genes. These genes include receptors for chemokines, interleukins, TNFα, and these harmful proteins, as well as many other proteins. Therefore, the inhibition of NF-κB activation by the disclosed peptides also prevents other symptoms that may be caused by chemokines, cytokines, TNFα, and related receptor proteins. Since these molecules also contribute to NF-κB activation, it can be seen how the disclosed peptides that inhibit NF-κB activation halt a self-sustaining feedback system. This positive feedback system is as follows: Figure 1B As shown.

[0389] TGF-β is a negative regulator of the cell cycle, leading to growth arrest by directly affecting the cell cycle. TGF-β binding results in the formation of heterooligomeric complexes of different type I and type II serine / threonine kinase receptors, which can transduce signals via Smad proteins (a class of transcription factors). Smad signaling requires the binding of growth factors to the type II TGF-β receptor (TBRII), followed by the interaction of the TBRII-growth factor complex with the type I TGF-β receptor (TBRI), leading to TBRI phosphorylation. TBRI phosphorylation results in Smad2 phosphorylation, which subsequently binds to Smad4. This complex then translocates to the nucleus, leading to transcriptional regulation of a series of target genes. TBRII plays a crucial role in TGF-β signaling. Radiation- or oxidative-induced mutations or downregulation of TBRII can lead to a wide range of diseases, including severe inflammatory diseases, neurodegenerative diseases, cancer, immune system disorders, impaired repair, kidney disease, and vascular diseases, including aneurysms.

[0390] like Figure 12A and Figure 12BAs shown, the peptide LIANAK (SEQ ID NO:060, “Leu-6Lys” in the figure) disclosed herein can bypass the receptor step and induce Smad signaling. Smad signaling was compared in HepG2 cells containing a complete signaling system and MCF-7 cells lacking a functional TBRII. HepG2 cells responded to both TGF-β and LIANAK (SEQ ID NO:060) with the same smad2 phosphorylation levels. Conversely, only the peptide was able to induce smad2 phosphorylation in TBRII-deficient MCF-7 cells. Furthermore, SB431542 (4-[4-(1,3-benzodioxane-5-yl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzamide, a potent TBRII inhibitor) did not affect peptide-induced smad2 phosphorylation. Therefore, it can be inferred that the function of the peptide is completely different from that of TGF-β. The peptide described herein can be used to treat diseases in which TGF-β signaling is limited due to the lack of a functional TBRII.

[0391] definition

[0392] The following definitions are used in this article.

[0393] The term "object," "individual," or "patient" is a vertebrate, preferably a mammal, and more preferably a human. In other embodiments, the object, individual, or patient is a food animal, such as a chicken, turkey, duck, goose, cow, lamb, sheep, pig, or goat. In other embodiments, the object, individual, or patient is a domesticated animal, such as a cat, dog, bird, rabbit, or guinea pig. The compounds, compositions, and methods disclosed in this invention are suitable for use in human medicine and veterinary medicine.

[0394] "Treating" a disease or condition using the compounds and methods discussed herein is defined as administering one or more of the compounds discussed herein (with or without additional therapeutic agents) to reduce or eliminate the disease or condition or one or more symptoms of the disease or condition, or to delay the progression of the disease or condition or one or more symptoms of the disease or condition, or to alleviate the severity of the disease or condition or one or more symptoms of the disease or condition. "Inhibiting" a disease or condition using the compounds and methods discussed herein is defined as administering one or more of the compounds discussed herein (with or without additional therapeutic agents) to inhibit the clinical manifestations of the disease or condition, or to inhibit the adverse symptom manifestations of the disease or condition. The distinction between treatment and inhibition is that treatment is performed after an individual has exhibited adverse symptoms of the disease or condition, while inhibition is performed before an individual has exhibited adverse symptoms of the disease or condition. Inhibition can be partial inhibition, substantially complete inhibition, or complete inhibition.

[0395] The "therapeutic use" of the compounds discussed herein is defined as the use of one or more of the compounds discussed herein to treat or inhibit a disease or condition as described above. The "therapeutic effective amount" of a compound is the amount of compound, when administered to an individual, sufficient to reduce or eliminate one or more symptoms of the disease or condition, or delay the progression of the disease or condition, or alleviate the severity of the disease or condition, or inhibit the clinical manifestations of the disease or condition, or inhibit adverse symptom manifestations of the disease or condition. Therapeutic effective amounts may be administered once or in multiple divided doses.

[0396] The singular forms “a,” “a,” “or,” and “the” used in this document include their plural forms unless the context clearly indicates otherwise.

[0397] The numerical values ​​or parameters mentioned in this article that include or describe variations of the numerical value or parameter itself, as well as other numerical values ​​included in "approximately". For example, "approximately X" includes a description of the numerical value "X".

[0398] "Administering the drug near the affected area" refers to administering a compound that inhibits NF-κB activity close enough to the site of disease so that the compound can have a therapeutic effect on the disease.

[0399] "Inhibitor of NF κB", "inhibitory of NF κB", and "NF κB inhibitor" refer to compounds that inhibit the activation or activity of NF κB through any mechanism. The terms "inhibitor of NF κB", "inhibitory of NF κB", and "NF κB inhibitor" do not require or necessarily imply direct binding to NF κB; such binding may or may not occur when NF κB activity is inhibited.

[0400] "Peptide-like" refers to a peptide-like polymer containing poly-N-substituted glycine. In peptide-like, an amino acid monomer is attached to the amino group by a side chain that would otherwise be linked to the α-carbon of the amino acid, and the side chain at the α-carbon is replaced by a hydrogen-substituted monomer. Peptides used in this invention have the same sequence as the peptides shown herein, wherein the peptide residues are replaced by their peptide-like equivalents (e.g., alanine in the peptide is replaced by N-methylglycine). When the residues shown in the sequence already have non-hydrogen amino substituents (e.g., proline), these residues remain unchanged when present in the peptide-like.

[0401] “Peptide mimics” are peptides in which one or more peptide bonds are replaced by ester bonds (-(C=O)-O- instead of -(C=O)-NH-; condensed peptides), one or more peptide bonds are replaced by thioester bonds (-(C=O)-S- instead of -(C=O)-NH-), or the carbonyl group of one or more peptide bonds is replaced by a methylene group (-(CH2)-NH- instead of –(C=O)-NH-; reduced amide bonds). Methods for preparing condensed peptides are described in Stawikowski et al., Methods Mol. Biol. 386:321-39 (2007) and Albericio et al., Org. Lett. 7(4):597-600 (2005). Methods for preparing peptides containing thioester bonds are described in Raz et al., Org. Lett. 13(7):1606-1609 (2011) and Stuhr-Hansen et al., European Journal of Organic Chemistry 2013(24):5290-5294 (2013). Methods for preparing peptides containing reduced amide bonds are described in Sasaki et al., Peptides 8(1):119-121 and Meyer et al., J. Med. Chem. 38(18):3462-3468 (1995).

[0402] Although the peptide compounds described herein may be present and used as neutral (non-salt) peptide compounds (including amphoteric non-salt compounds), this specification is intended to include all salts of the compounds described herein, as well as methods of using these salts. In one embodiment, the salt of the compound comprises a pharmaceutically acceptable salt. A pharmaceutically acceptable salt is a salt that can be administered to humans and / or animals as a drug or pharmaceutical product, wherein the salt retains at least some of the biological activity of the free compound (neutral or non-salt compound) upon administration. The desired salt of the basic compound can be prepared by methods known to those skilled in the art, by treating the compound with an acid. Examples of inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Examples of organic acids include, but are not limited to, formic acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, sulfonic acid, and salicylic acid. Salts of basic compounds with amino acids, such as aspartate and glutamate, can also be prepared. Salts of the desired acidic compounds can be prepared by methods known to those skilled in the art, by treating the compound with an alkali. Examples of inorganic salts of acidic compounds include, but are not limited to, alkali metal and alkaline earth metal salts, such as sodium, potassium, magnesium, and calcium salts; ammonium and aluminum salts. Examples of organic salts of acidic compounds include, but are not limited to, procaine, dibenzylamine, N-ethylpiperidine, N,N-dibenzylethylenediamine, and triethylamine salts. Salts of acidic compounds with amino acids such as lysine can also be prepared.

[0403] Compounds can be administered as prodrugs. A prodrug is a derivative of a compound that is relatively inactive on its own, but which, upon introduction into an individual, can be converted into an active compound through in vivo chemical or biological processes such as enzymatic conversion. Suitable prodrug formulations include, but are not limited to, peptide conjugates and esters of the compounds disclosed herein. Other discussions on appropriate prodrugs can be found in H. Bundgaard, Design of Prodrugs, New York: Elsevier, 1985; R. Silverman, The Organic Chemistry of Drug Design and Drug Action, Boston: Elsevier, 2004; RL Juliano (ed.), Biological Approaches to the Controlled Delivery of Drugs (Annual Report of the New York Academy of Sciences, v. 507), New York: New York Academy of Sciences, 1987; and E.B. Roche (ed.), Design of Biopharmaceutical Properties Through Prodrugs and Analogs (Pharmaceutical Chemistry Symposium, APhA Academy of Pharmaceutical Sciences, National Conference, November 1976, Orlando, Florida), Washington: The Academy, 1977.

[0404] Gene expression data: Gene expression data in cells treated with NF-κB-inhibit peptides are shown to support the unique biological characteristics of these compounds as potential therapeutic agents. Figure 7 Genes that may be affected by SEQ ID NO:010 are listed.

[0405] Peptides delay cell proliferation: The cell cycle is subject to numerous controls to ensure proper cell division. The duration of each phase of the cell cycle is controlled by checkpoints. Modifying the duration of each phase under checkpoint control plays a crucial role in cancer (Bartek and Lukas, Curr. Opin. Cell Biol. 13(6):738-747 (2001); Bartek and Lukas, Science 294(5540):66-7 (2001); Bartek and Lukas, FEBS Lett. 490(3):117-122 (2001)). Apoptosis is closely related to proliferation. Some cell cycle regulators can influence cell division and programmed cell death. Therefore, targeting the cell cycle offers unique opportunities for cancer therapy.

[0406] The effects of NF-κB inhibitor peptides on growth arrest were investigated. TGFβ is known to cause G1 phase arrest in cell growth, while NF-κB inhibitor peptides significantly prolong the S phase. Radiation, free radicals, and cytotoxic therapies target rapidly differentiating disease cells, such as cancer cells. By prolonging the S phase, NF-κB inhibitor peptides provide protection for cells that do not undergo rapid division during these cytotoxic treatments. Therefore, NF-κB inhibitor peptides could be used as a protective measure for cells and tissues before receiving cytotoxic therapy.

[0407] Description of the compounds used in this invention: The compounds of this invention are peptides, peptide mimics, or peptide-like compounds of 4-20 residues. In this application, peptide refers to peptides, peptide mimics, and peptide-like compounds. The term "standard peptide" refers to a polymer of α-amino acids and / or imines (e.g., proline) without peptide bond modifications, i.e., peptides excluding peptide-like compounds and peptide mimics. The compounds used in this invention have a specific tripeptide core sequence in their peptide structure, as described below. The purpose of this peptide is to mimic a common conformational feature present in protein kinases, including serine-threonine kinases and protein-tyrosine kinases. These peptides can masquerade the conformation of certain interacting domains in stimulatory signaling protein kinases and can act as molecular decoys to modulate kinase activity through allosteric mechanisms.

[0408] The peptides used in this invention are characterized by important physicochemical properties that mimic the structural features of certain interactions in serine and threonine kinases. These features can be simulated by a number of amino acid sequences. The activity of these peptides depends on one or more adjacent sequences present in the structure of the peptide. This sequence will be referred to below as the “core sequence.” The core sequence consists of four residues and mimics the surface of certain interacting sites present in many protein kinases, including protein tyrosine and serine / threonine kinases. While these domains do not participate in the catalytic activity of the enzyme, their presence in the enzyme and in the substrate protein kinase is essential for intermolecular recognition and interaction. The peptides are designed based on the following arguments: the interaction sites on the protein need to be close to the surface; they can exist in more than one isoenergetic conformation, one of which presents the optimal surface for coupling with complementary acceptor sites on the interacting chaperone; the interaction is well-developed by induced fit; the interaction typically involves weak bonds; and finally, the interacting domain does not need to be large. We have conducted computer simulations to study the interactions between various disclosed peptides and some protein kinases, and our studies have confirmed stable peptide-kinase interactions. Specifically, these studies predict interactions with similar acceptor sites on different kinases. Therefore, we hypothesize that these peptides alter kinase activity by mimicking specific molecular domains on protein A through the interaction of a chaperone (protein A) with a specific receptor site on protein B. Thus, this peptide can be termed a molecular decoy. The core sequence essential for the activity of this peptide is described below. While many of the amino acid residues listed here are not naturally present in animal proteins, they are included here because they provide a peptide surface that mimics the domains found in a variety of enzymes and proteins associated with NF κB activation.

[0409] The peptides disclosed herein contain various core sequences that have been found to confer NF-κB inhibitory activity. These peptides can be four to twenty, four to fifteen, four to twelve, four to ten, four to eight, six to twenty, six to fifteen, six to twelve, six to ten, or six to eight amino acids long, as long as the peptide contains a suitable core sequence. For a specified peptide containing a particular sequence, the lower limit of the peptide length is the specified sequence, and the upper limit of the peptide length can be twenty, fifteen, twelve, ten, or eight amino acids, provided that the upper limit of the peptide length is greater than or equal to the lower limit of the peptide length (i.e., the upper limit of the peptide length cannot be longer than the specified sequence segment in the peptide).

[0410] Core sequence (1): Xxx-Ala-Pro-Glu, where Xxx is Met, Ile, Val, Cys, Trp, Tyr, Phe, 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthopropionic acid, β-cyclohexyl-Ala, dehydroalanine, or β-tert-butyl-Ala

[0411] Core sequence (2): Xxx-Ala-Pro-(D)Glu, where Xxx is Met, Ile, Val, Cys, Trp, Tyr, Phe, 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthopropionic acid, β-cyclohexyl-Ala, dehydroalanine, or β-tert-butyl-Ala

[0412] Core sequence (3): Xxx-Ala-Glu-Ala, where Xxx is Met, Ile, Val, Cys, Trp, Tyr, Phe, 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthopropionic acid, β-cyclohexyl-Ala, dehydroalanine, or β-tert-butyl-Ala

[0413] Core sequence (4): Xxx-Ala-[D]Glu-Ala, where Xxx is Met, Ile, Val, Cys, Trp, Tyr, Phe, 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthopropionic acid, β-cyclohexyl-Ala, dehydroalanine, or β-tert-butyl-Ala

[0414] Core sequence (5): Xxx-Ala-Asn-Ala, where Xxx is Met, Ile, Val, Cys, Trp, Tyr, Phe, 5-methyl-Trp, allo-Ile, β-styryl-Ala, naphthyl-Ala, diphenyl-Ala, α-aminobutyric acid, α-aminohexanoic acid, leucine, α-amino-2-phenylbutyric acid, α-amino-1-naphthopropionic acid, β-cyclohexyl-A...

Claims

1. An in vitro method for inhibiting NFκB activation or activity in cells, tissues or organs, comprising contacting cells, tissues or organs with an effective amount of a peptide, wherein the peptide is LFAP[D]EA (SEQ ID NO: 013).

2. A peptide, wherein the peptide is LFAP[D]EA (SEQ ID NO: 013).

Images